Drugs / Recombinant Human rEGF-P64K/Montanide Vaccine
Recombinant Human rEGF-P64K/Montanide Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00516685 | Jul 2007 → ? | non-small cell lung carcinoma | Bioven Sdn. Bhd. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human rEGF-P64K/Montanide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00516685 ↗ |
| Modality | Vaccine | “the recombinant human rEGF-P64K/Montanide ISA 51 vaccine” NCT00516685 ↗ |